Adial Pharmaceuticals, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ADIL Nasdaq 2830 www.adial.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing - Jun 16th, 2026 6:00 am
Sector Update: Healthcare Stocks Higher Late Afternoon - Jun 11th, 2026 1:28 pm
ADIL Stock Eyes Best Day In Over 5 Years — Major Pipeline Overhaul And $64M Raise Fuel Rally - Jun 11th, 2026 11:04 am
Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing - Jun 11th, 2026 9:43 am
Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight - Jun 8th, 2026 11:00 am
Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update - May 11th, 2026 6:30 am
Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045 - Apr 29th, 2026 7:07 am
Adial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program - Apr 27th, 2026 6:47 am
Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial - Apr 22nd, 2026 7:35 am
Adial Pharmaceuticals Commends Congress on Introduction of Bipartisan Legislation Expanding Access to Emerging AUD Therapies for Veterans - Mar 24th, 2026 7:07 am
Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update - Mar 6th, 2026 6:00 am
Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement - Mar 3rd, 2026 6:17 am
Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement - Feb 24th, 2026 7:00 am
Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One - Feb 23rd, 2026 6:30 am
Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Feb 17th, 2026 7:00 am
Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04 - Feb 4th, 2026 7:35 am
Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement - Feb 3rd, 2026 2:05 pm
Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045 - Jan 14th, 2026 7:00 am
Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year? - Jan 6th, 2026 7:40 am
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross Proceeds - Nov 26th, 2025 6:00 am